Introduction
============

Gastric cancer (GC) is the second most common cause of cancer-related mortality worldwide, including many Asian countries.[@b1-cmar-10-315],[@b2-cmar-10-315] Most GC patients are diagnosed at advanced stage and have poor survival. As a result, there is a need to obtain an accurate, costless, and easily accessible marker to evaluate the prognosis of curative resection GC patients.

In clinical practice, many studies reported that the systemic inflammatory response was associated with postoperative survival of patients with several types of cancer, such as gastric, lung, colorectal, and head and neck cancer.[@b3-cmar-10-315]--[@b6-cmar-10-315] Recently, many markers of inflammatory response, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP), albumin (Alb), globulin, and the Glasgow Prognostic Score (GPS) were demonstrated as independent predictive factors of GC.[@b7-cmar-10-315]--[@b12-cmar-10-315] In addition, some kinds of the combined markers were also studied in other cancers. Zhang et al and Ishizuka et al reported that the combination of preoperative platelet count and NLR was able to predict the prognosis of patients and direct clinical treatment with lung cancer and colorectal cancer, respectively.[@b13-cmar-10-315],[@b14-cmar-10-315] Huang et al found that the combination of CRP and carcinoembryonic antigen was superior to CRP or CEA as a more precise prognostic factor in patients with esophageal carcinoma.[@b15-cmar-10-315] However, the role of combination of these inflammatory biomarkers in accessing GC prognosis is less well-known. We conducted a systematic literature review and surprisingly found that the significance of the combination of CRP and NLR (COC-NLR) for GC had not been studied yet. Therefore, we collected related data and designed this retrospective study to explore the relationship between COC-NLR and the prognosis of GC patients.

Materials and methods
=====================

Study population and data collection
------------------------------------

A retrospective review was performed by using a database of 1,058 GC patients who had undergone D2 gastrectomy with R0 resection between December 2003 and January 2013 in Cancer Center of Sun Yat-Sen University Cancer Center (Guangzhou, China). The inclusion criteria were as follows: 1) patients were confirmed as stage I--III histologically; 2) patients underwent D2 gastrectomy with R0 resection; 3) patients whose number of lymph nodes retrieved were no less than 15; 4) no acute or chronic inflammation, immune disease, hematological disease, liver disease, or concomitant cancer that could influence the level of the biomarkers; 5) no neoadjuvant chemotherapy or radiotherapy; 6) completed follow-up data.

Various potential prognostic factors were investigated, including age, sex, preoperative blood variables, metastatic lymph node ratio, tumor location, histological type, and tumor-node-metastasis (TNM) stage (American Joint Committee on Cancer criteria, AJCC criteria 7th edition).[@b16-cmar-10-315]--[@b18-cmar-10-315] Data were obtained from our hospital cancer registry. All patients were followed up regularly until December 2016 or until death or the day of cancer recurrence. The median follow-up period was 35 months. Overall survival (OS) was calculated from the date of surgery to the date of death or last follow-up.

The Alb globulin ratio (AGR) is calculated by measured total protein, measured Alb, and calculated globulin (total protein -- Alb).[@b7-cmar-10-315],[@b19-cmar-10-315] The NLR and PLR were defined as the absolute neutrophil count or platelet count divided by the absolute lymphocyte count, respectively.[@b20-cmar-10-315] The systemic immune inflammation index (SII) was calculated as follows: SII = P × N/L (P: platelet counts, N: neutrophil counts, L: lymphocyte counts).[@b21-cmar-10-315] Using standard thresholds (\>10 mg/L for CRP and \<35 g/L for Alb), the GPS was calculated by Alb and CRP. The CRP/Alb ratio was defined as the ratio of preoperative serum CRP level divided by the serum Alb level.[@b22-cmar-10-315]

The study was approved by the Research Ethics Committee of Sun Yat-Sen University Cancer Center. Written informed consent was obtained from all individual participants included in the study.

Random forest analysis
----------------------

Breiman et al proposed random forests, which added an additional layer of randomness to bagging. In addition to constructing each tree using a different bootstrap sample of the data, random forests change how the classification and regression trees are constructed.[@b23-cmar-10-315] R Statistical Software was used to discover the optimal cutoff points of the NLR and CRP based on the outcome. The random forest algorithm package was used to evaluate the levels of the NLR and CRP ([Figure 1](#f1-cmar-10-315){ref-type="fig"}).

Statistical analysis
--------------------

χ^2^ test was used for categorical variables. The optimal cutoff values were obtained by the Youden index.[@b24-cmar-10-315] Variables proved to be statistically significant in the univariate analysis were included into the Cox multivariable analysis. The discriminatory ability of the factors to predict survival time was assessed using the area under the curve (AUC) method. Kaplan--Meier curve was used for survival analysis.

When the *p* value was \<0.05, the result was statistically significant. All statistical analyses were performed by the software statistical package for social sciences version 19.0 (IBM Corporation, Armonk, NY, USA) and the R software version 3.13 (<http://www.r-project.org/>).

Results
=======

Based on the cutoff values, 1,058 patients were classified into three groups (low: NLR ≤2.5, CRP ≤6.1; medium: NLR \>2.5, CRP ≤4.5; high: NLR \>2.5, CRP \>4 or NLR ≤2.5, CRP \>6.1). The three groups had 581, 187, and 290 patients, respectively. The relationship between COC-NLR and clinicopathological characteristics are shown in [Table 1](#t1-cmar-10-315){ref-type="table"}. In the three groups, no significant correlations were found in sex, level of lymphocytes, and Alb. There were significant differences among the three groups, including age, neutrophils, platelet, CRP, AGR, NLR, PLR, SII, GPS, modified GPS (mGPS), high-sensitivity mGPS (HS-mGPS), CRP/Alb ratio, tumor location, tumor size, metastatic lymph node ratio, histological type, and TNM stage.

Associations between each variable and OS were presented in [Table 2](#t2-cmar-10-315){ref-type="table"}, in which univariate analysis and multivariate Cox regression were performed. Significant variables (age, neutrophils, platelets, CRP, AGR, NLR, PLR, SII, GPS, mGPS, HS-mGPS, CRP/Alb ratio, tumor location, tumor size, metastatic lymph node ratio, histological type, and TNM stage) in the univariate analysis were included in the multivariate Cox proportional hazard model. The multivariate analysis indicated that age, neutrophils, CRP, AGR, HS-mGPS, tumor location, tumor size, metastatic lymph node ratio, histological type, and TNM stage were independent prognostic factors for survival time of patients.

The predictive values of independent factors (neutrophils, CRP, AGR, and HS-mGPS) were assessed by the receiver operating characteristic (ROC) curve method. With the highest AUC (1 year: 0.662, 95% CI: 0.609--0.715, *p*\<0.01; 3 years: 0.644, 95% CI: 0.611--0.677, *p*\<0.01; 5 years: 0.655, 95% CI: 0.614--0.696, *p*\<0.01), the COC-NLR had the optimal discrimination ability which clearly showed that it is superior to other inflammatory markers ([Figure 2](#f2-cmar-10-315){ref-type="fig"}, [Table 3](#t3-cmar-10-315){ref-type="table"}).

We used Kaplan--Meier curves to assess the survival time of patients in different groups. The mean OS of the high, medium, and low groups was 38.7 (95% CI: 21.3--27.1), 56.5 (95% CI: 50.7--62.3), and 75.4 (95% CI: 72.5--78.4) months, respectively ([Figure 3A](#f3-cmar-10-315){ref-type="fig"}). Because GC patients of stage I always had good prognosis, we performed subgroup analysis in stage II ([Figure 3B](#f3-cmar-10-315){ref-type="fig"}) and stage III ([Figure 3C](#f3-cmar-10-315){ref-type="fig"}). We found patients in the low group had better survival than the medium group and the high group.

Discussion
==========

In this report, we first proved that the preoperative COC-NLR was associated with the prognosis of GC patients. Moreover, COC-NLR was a better prognostic factor compared to use CRP or NLR only. The high group of the preoperative COC-NLR was associated with adverse survival probabilities in GC.

Indeed, as the important markers of inflammation response, the prognostic values of CRP and NLR have been given great concern. Nozoe et al found that GC patients with preoperative CRP elevation usually had shorter survival time.[@b25-cmar-10-315] Lee et al and Sun et al reported that high level of NLR predicted poor outcome of GC patients. Besides, the measurement of NLR may be used for personalized cancer care in the future.[@b26-cmar-10-315],[@b27-cmar-10-315] Interestingly, our results were in accordance with the previous studies.[@b25-cmar-10-315]--[@b27-cmar-10-315]

Survival analysis showed that CRP has statistical significance in both univariate (*p*\<0.01) and multivariate (*p*\<0.01) analyses. But NLR has statistical significance in univariate analysis only (*p*\<0.01). The group with lower level of CRP also exhibited better survival than the higher group, which indicated that CRP was a negative factor for the prognosis of GC. However, the ROC curve showed that COC-NLR could provide more accurate prediction than any other conventional inflammatory markers in this study, including single CRP. Meanwhile, it was also verified in our subgroup survival analysis.

As a relatively simple, convenient, and cheap model, COC-NLR is easy to measure in clinical practice. D2 gastrectomy is the cornerstone of treatment for patients suffering from localized GC.[@b28-cmar-10-315] However, GC metastases early via blood, lymphatic system, and peritoneum. Even after R0 resection, almost 40% of GC patients relapse within 2 years after gastrectomy. The median OS after recurrence is as low as 7.4 months in patients with distant metastases and 10.4 months in patients with local recurrence.[@b29-cmar-10-315] Therefore, as an accurate marker, COC-NLR can help us to predict recurrence ahead and make decisions in the management of GC patients, including selection of adjuvant therapies and determining follow-up arrangements. According to our study, high group had the poorest prognosis. For this group of patients, more powerful adjuvant chemotherapy may be used to prevent recurrence and prolong survival postoperatively. As generally known, there is strong linkage between inflammation and chemotherapy. Short survival time is always related to low chemosensitivity. Therefore, more frequent follow-up should be performed postoperatively for patients with high-risk recurrence in order to choose suitable therapies.

As an effective biomarker, COC-NLR could predict the prognosis of GC patients better than many other well-established systemic inflammation-based prognostic markers. Based on such a large cohort study, our results were reliable. We supposed that the potential mechanism may be as follows. Recently, some studies[@b30-cmar-10-315]--[@b32-cmar-10-315] demonstrated that the survival of cancer patients was determined by tumor-related factors and host-related factors simultaneously. Cancer-related inflammation can affect cell proliferation, invasion, metastasis, cell survival, tumor--cell migration, and angiogenesis. On the one hand, inflammation contributed to tumorigenesis. On the other hand, the tumor itself could release inflammatory mediators and cause inflammatory response.[@b30-cmar-10-315]--[@b32-cmar-10-315]

As a valuable classification algorithm, random forest has been used in many fields, including gene selection, classification of microarray data, prediction of protein--protein interactions, and so on.[@b33-cmar-10-315],[@b34-cmar-10-315] Our study first used the method to find out the cutoff points of two biomarkers, which helped us to perform a more powerful and accurate data processing.

However, our study still had some limitations. First, it was a retrospective and single-institution study, which needs further validation in the future. Second, our result cannot be used to assess the prognosis of stage IV GC patients.

It is well-known that CRP and NLR are easy to measure routinely. As a novel combination of these two significant prognostic factors, COC-NLR is better in predicting the prognosis and indicating the treatment for GC patients.
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![Random forest analysis for the optimal cutoff points.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein.](cmar-10-315Fig1){#f1-cmar-10-315}

![(**A**--**C**) The predictive abilities of the inflammatory markers were compared by receiver operating characteristic curves for 1, 3, and 5 years.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR; AGR, albumin globulin ratio; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score.](cmar-10-315Fig2){#f2-cmar-10-315}

![(**A**) The optimal survival curves of all patients according to the different levels of COC-NLR. (**B**) The optimal survival curves of stage II patients according to the different levels of COC-NLR. (**C**) The optimal survival curves of stage III patients according to the different levels of COC-NLR.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR.](cmar-10-315Fig3){#f3-cmar-10-315}

###### 

Relationship between COC-NLR and clinicopathologic characteristics

  --------------------------------------------------------------------------------
  Variable                              Low\      Medium\   High\     *p*-value
                                        (n=581)   (n=187)   (n=290)   
  ------------------------------------- --------- --------- --------- ------------
  Patient-related factors                                             

  Sex                                                                 0.228

   Male                                 381       130       206       

   Female                               200       57        84        

  Age (years)                                                         **0.019**

   \<65                                 421       129       183       

   ≥65                                  160       58        107       

  Neutrophils (×10^9^/L)                                              **\<0.01**

   \<3.61                               382       40        60        

   ≥3.61                                119       147       230       

  Lymphocytes (×10^9^/L)                                              0.238

   \<3.56                               581       155       244       

   ≥3.56                                0         32        46        

  Platelets (×10^9^/L)                                                **\<0.01**

   \<315.5                              511       157       206       

   ≥315.5                               70        30        84        

  CRP (mg/L)                                                          **\<0.01**

   \<4.29                               546       183       0         

   ≥4.29                                35        4         290       

  Albumin (g/L)                                                       0.166

   \<48.45                              566       183       288       

   ≥48.45                               15        4         2         

  AGR                                                                 **0.03**

   \<1.09                               6         3         13        

   ≥1.09                                575       184       277       

  NLR                                                                 **\<0.01**

   \<2.5                                581       155       244       

   ≥2.5                                 0         32        46        

  PLR                                                                 **\<0.01**

   \<125.31                             358       45        97        

   ≥125.31                              223       142       193       

  SII                                                                 **\<0.01**

   \<521.56                             457       24        82        

   ≥521.56                              124       163       208       

  GPS                                                                 **\<0.01**

   0                                    561       176       112       

   1                                    20        11        132       

   2                                    0         0         46        

  mGPS                                                                **\<0.01**

   0                                    505       155       6         

   1                                    72        32        174       

   2                                    4         0         110       

  HS-mGPS                                                             **\<0.01**

   0                                    476       142       0         

   1                                    99        44        232       

   2                                    6         1         58        

  CRP/Alb ratio                                                       **\<0.01**

   \<0.096                              581       187       323       

   ≥0.096                               0         0         58        

  Tumor-related factors                                               

   Tumor location                                                     **\<0.01**

   Lower third                          260       70        87        

   Middle third                         121       35        50        

   Upper third                          200       82        153       

  Tumor size (cm)                                                     **\<0.01**

   \<2.9                                165       35        27        

   ≥2.9                                 416       152       263       

  Histological type                                                   **\<0.01**

   Poor-differentiated adenocarcinoma   366       99        196       

   Other                                215       88        94        

  Metastatic lymph node ratio                                         **\<0.01**

   \<0.18                               368       105       119       

   ≥0.18                                213       82        171       

  TNM stage                                                           **\<0.01**

   IA                                   82        21        9         

   IB                                   52        20        11        

   IIA                                  58        20        11        

   IIB                                  102       25        43        

   IIIA                                 69        16        37        

   IIIB                                 109       42        64        

   IIIC                                 109       43        115       
  --------------------------------------------------------------------------------

**Notes:** Low: NLR ≤2.5, CRP ≤6.1; medium: NLR \>2.5, CRP ≤4.6; high: NLR \>2.5, CRP \>4 or NLR ≤2.5, CRP \>6.1. Bold figures represent as statistically significant, *p*\<0.05.

**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR; AGR, albumin globulin ratio; GPS, Glasgow Prognostic Score; mGPS, modified Glasgow Prognostic Score; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score; TNM, tumor-node-metastasis; Alb, albumin; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index.

###### 

Hazard ratios of baseline characteristics for all-cause mortality in gastric cancer patients (univariate and multivariate analyses)

                                                                Univariate analysis HR (95% CI)   *p*-value    Multivariate analysis HR (95% CI)   *p*-value
  ------------------------------------------------------------- --------------------------------- ------------ ----------------------------------- ------------
  Patient-related factors                                                                                                                          
  Sex (male/female)                                             1.019 (0.825--1.257)              0.863                                            
  Age (years) (\<65/≥65)                                        1.514 (1.234--1.857)              **\<0.0**1   1.604 (1.289--1.997)                **\<0.01**
  COC-NLR (ref: low)                                                                              **\<0.01**                                       \<0.01
   Medium                                                       1.863 (1.403--2.474)                           1.693 (1.195--2.397)                \<0.01
   High                                                         4.223 (3.382--5.271)                           2.698 (1.504--4.841)                \<0.01
  Neutrophils (×10^9^/L)(\<3.61/≥3.61)                          2.075 (1.684--2.558)              **\<0.01**   1.371 (1.052--1.785)                **0.02**
  Lymphocytes (×10^9^/L)(\<3.56/≥3.56)                          0.927 (0.414--2.077)              0.855                                            
  Platelet (×10^9^/L)(\<315.5/≥315.50)                          1.422 (1.117--1.810)              **0.004**    1.105 (0.822--1.485)                0.51
  CRP (mg/L) (\<4.29/≥4.29)                                     3.265 (2.676--3.983)              **\<0.01**   1.149 (0.607--2.176)                **\<0.01**
  Albumin (g/L) (\<48.45/≥48.45)                                1.459 (0.821--2.592)              0.198                                            
  AGR (\<2.5/≥2.5)                                              0.210 (0.169--0.262)              **\<0.01**   2.847 (1.331--6.091)                **\<0.01**
  NLR (\<2.5/≥2.5)                                              0.210 (0.169--0.262)              **\<0.01**   1.345 (0.965--1.875)                0.08
  PLR (\<125.31/≥125.31)                                        1.443 (1.181--1.763)              **\<0.01**   1.105 (0.822--1.485)                0.51
  SII (\<521.56/≥521.56)                                        1.762 (1.444--2.151)              **\<0.01**   0.795 (0.573--1.103)                0.17
  GPS (ref: 0)                                                                                    **\<0.01**                                       0.21
   1                                                            2.297 (1.808--2.919)              \<0.01       0.868 (0.618--1.219)                0.42
   2                                                            3.689 (2.551--5.336)              \<0.01       0.443 (0.179--1.097)                0.08
  mGPS (ref: 0)                                                                                   **\<0.01**                                       0.14
   1                                                            0.312 (0.235--0.414)              \<0.01       1.052 (0.709--1.559)                0.80
   2                                                            0.762 (0.569--1.020)              0.068        0.689 (0.386--1.229)                0.21
  HS-mGPS (ref: 0)                                                                                **\<0.01**                                       **0.02**
   1                                                            2.579 (2.091--3.181)              \<0.01       0.987 (0.668--1.459)                0.74
   2                                                            4.124 (2.944--5.775)              \<0.01       2.764 (1.242--6.150)                0.06
  CRP/Alb ratio (\<0.096/≥0.096)                                2.945 (2.076--4.179)              **\<0.01**   1.501 (0.910--2.477)                0.11
  Tumor-related factors                                                                                                                            
   Tumor location (ref: lower)                                                                    **\<0.01**                                       **\<0.01**
   Middle                                                       1.412 (1.051--1.895)              0.022        1.312 (0.970--1.776)                0.08
   Upper                                                        2.453 (1.946--3.092)              \<0.01       1.813 (1.417--2.319)                **\<0.01**
  Tumor size (cm) (\<2.9/≥2.9)                                  3.051 (2.207--4.217)              **\<0.01**   0.933 (0.651--1.338)                0.71
  Histological type (ref: poor-differentiated adenocarcinoma)   1.365 (1.104--1.687)              **\<0.01**   0.718 (0.575--0.897)                **\<0.01**
  Metastatic lymph node ratio (\<0.18/≥0.18)                    4.753 (3.817--5.919)              **\<0.01**   2.099 (1.526--2.888)                **\<0.01**
  TNM stage (ref: IA)                                                                             **\<0.01**                                       **\<0.01**
   IB                                                           0.037 (0.015--0.091)              \<0.01       1.625 (0.513--5.147)                0.41
   IIA                                                          0.072 (0.034--0.153)              \<0.01       3.153 (1.094--9.089)                0.03
   IIB                                                          0.129 (0.072--0.231)              \<0.01       4.765 (1.833--12.389)               0.01
   IIIA                                                         0.235 (0.167--0.331)              \<0.01       5.992 (2.286--15.710)               \<0.01
   IIIB                                                         0.377 (0.269--0.527)              \<0.01       7.352 (2.807--19.254)               \<0.01
   IIIC                                                         0.631 (0.497--0.802)              \<0.01       9.639 (3.620--25.669)               \<0.01

**Note:** Bold figures represent as statistically significant, *p*\<0.05.

**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR; AGR, albumin globulin ratio; GPS, Glasgow Prognostic Score; mGPS, modified Glasgow Prognostic Score; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score; TNM, tumor-node-metastasis; Alb, albumin; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index; HR, hazard ratio; Ref, reference.

###### 

Comparison of the AUCs for the five inflammatory markers

                AUC     95% Cl         *p*-value
  ------------- ------- -------------- -----------
  **1 year**                           
  AGR           0.512   0.458--0.565   0.671
  Neutrophils   0.597   0.545--0.648   \<0.01
  HS-mGPS       0.660   0.609--0.711   \<0.01
  CRP           0.641   0.587--0.695   \<0.01
  COC-NLR       0.662   0.609--0.715   \<0.01
  **3 years**                          
  AGR           0.504   0.470--0.539   0.807
  Neutrophils   0.586   0.552--0.620   \<0.01
  HS-mGPS       0.611   0.577--0.645   \<0.01
  CRP           0.618   0.584--0.651   \<0.01
  COC-NLR       0.644   0.611--0.677   \<0.01
  **5 years**                          
  AGR           0.502   0.454--0.549   0.946
  Neutrophils   0.586   0.540--0.633   \<0.01
  HS-mGPS       0.609   0.565--0.652   \<0.01
  CRP           0.608   0.506--0.651   \<0.01
  COC-NLR       0.655   0.614--0.696   \<0.01

**Abbreviations:** NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR; AGR, albumin globulin ratio; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score; AUC, area under the curve.

[^1]: These authors contributed equally to this work
